GUANGZHOU, China, Nov. 6, 2026 /PRNewswire/ -- Bio-Thera Solutions, Ltd. (688177.SH), a commercial-stage biopharmaceutical company developing innovative therapies and biosimilars, today announced that the National Medical Products Administration (NMPA) has approved its marketing authorization for BAT2506, a golimumab biosimilar.  This approval marks the first golimumab biosimilar approved in China.  BAT2506 will be marketed under the name 阿舒立^® (ASHULI) and is approved by NMPA for the following indications: rheumatoid arthritis and ankylosing spondylitis.